Does Seres Therapeutics Incorporated (NASDAQ:MCRB) Have Gas After Even More Sellers Involved?

February 15, 2018 - By Migdalia James

 Does Seres Therapeutics Incorporated (NASDAQ:MCRB) Have Gas After Even More Sellers Involved?

The stock of Seres Therapeutics Incorporated (NASDAQ:MCRB) registered an increase of 9.55% in short interest. MCRB’s total short interest was 4.60M shares in February as published by FINRA. Its up 9.55% from 4.20M shares, reported previously. With 171,100 shares average volume, it will take short sellers 27 days to cover their MCRB’s short positions. The short interest to Seres Therapeutics Incorporated’s float is 26.3%.

The stock increased 3.61% or $0.32 during the last trading session, reaching $9.19. About 76,854 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 64.58% since February 15, 2017 and is downtrending. It has underperformed by 81.28% the S&P500.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $372.47 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 9 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics Inc had 23 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, November 8 by Cantor Fitzgerald. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) earned “Buy” rating by Canaccord Genuity on Tuesday, August 25. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, August 30. Cowen & Co initiated the stock with “Outperform” rating in Monday, June 6 report. As per Friday, August 12, the company rating was maintained by FBR Capital. Cantor Fitzgerald maintained Seres Therapeutics, Inc. (NASDAQ:MCRB) on Thursday, October 19 with “Buy” rating. Canaccord Genuity initiated the shares of MCRB in report on Wednesday, July 22 with “Buy” rating. The stock has “Outperform” rating by FBR Capital on Wednesday, February 1. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) earned “Outperform” rating by Leerink Swann on Tuesday, July 21. The rating was maintained by Oppenheimer on Thursday, January 11 with “Buy”.

More notable recent Seres Therapeutics, Inc. (NASDAQ:MCRB) news were published by: Fool.com which released: “Here’s What’s Lifting Seres Therapeutics Inc.’s Stock Price Today” on March 16, 2017, also Marketwatch.com with their article: “Seres Therapeutics stock drops 19% on clinical trial results” published on October 02, 2017, Businesswire.com published: “Seres Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference” on January 04, 2018. More interesting news about Seres Therapeutics, Inc. (NASDAQ:MCRB) were released by: Businesswire.com and their article: “Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in …” published on December 04, 2017 as well as Businesswire.com‘s news article titled: “Seres Therapeutics Awarded Grant from CARB-X to Support Development of …” with publication date: November 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.